Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li>Tarsons Products is likely to announce its share allotment status today.</li><li>The grey market premium of the Indian labware company Tarsons Products has come down to ₹170 from ₹230 earlier.</li><li>The IPO of the company was subscribed 77.49 times on the last day of bidding.</li></ul>Indian labware company Tarsons Products is likely to announce the allotment status of its initial public offering (IPO) today, November 23. The IPO was open for subscription from November 15 to November 17. The company was looking to raise over ₹1,024 crore through the IPO of a fresh issue of equity shares worth ₹150 crore and an offer for sale (OFS) of 1.32 crore equity shares that will be sold by promoters and an investor <keyword id="12496770" type="General" weightage="20" keywordseo="tarsons-products-ipo" source="Orion">Tarsons Products IPO</keyword> received subscriptions for 77.49 times the number of shares offered in the three days of IPO bidding process. The grey market premium of the company’s shares show a premium of ₹170 from the higher end of the price band. The portion reserved for retail investors was oversubscribed by 10.56 times on the last day of the IPO bidding process. Tarsons Products is engaged in designing, developing, manufacturing and supplying a diverse range of quality labware products used in laboratories across research organisations, academic institutes, pharmaceutical firms, diagnostics companies and hospitals. Here is how to <keyword id="12587146" type="General" weightage="20" keywordseo="tarsons-products-ipo-allotment" source="Orion">Tarsons Products IPO allotment</keyword> status on stock exchange website: <ul><li>Go to the <a href="https://www.bseindia.com/investors/appli_check.aspx">BSE website</a> or NSE website<a href="https://www1.nseindia.com/products/dynaContent/equities/ipos/ipo_login.jsp"> here</a>.</li><li>On BSE, Select 'Equity' and then from the dropdown, select ‘Tarsons Products’.</li><li>Now, enter your application number and PAN.</li><li>Click on 'Search'.</li><li>Please note the details will only be available once the shares are allotted.</li></ul>You can also visit the registrar website (Link Intime India) to check your application status. <ul><li>Visit the registrar's website <a href="https://linkintime.co.in/MIPO/Ipoallotment.html">here</a>.</li><li>Click on 'Select company' and click on ‘Tarsons Products’.</li><li>Once the company is selected, you will have to enter either your PAN detail, the application number, or the client ID.</li><li>Enter the captcha and click ’submit’.</li></ul>Once you hit 'submit', the status of your application will appear on the screen. Please ensure the details that you provide are correct. It will show the number of shares you subscribed to and the number of shares allotted to you. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/latent-view-ipo-may-list-on-a-positive-note-despite-a-weak-market/articleshow/87850476.cms">Latent View IPO that got bigger traction than Paras Defence may list on a positive note despite a weak market</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/paytm-ccd-reliance-power-have-had-the-worst-stock-market-debut/slidelist/87845689.cms">Paytm, Cafe Coffee Day and Reliance Power — here’s are the worst stock market debut ever</a>

Tarsons Products IPO: Here’s how you can check the allotment status

<ul><li><keyword id="12496770" type="General" weightage="20" keywordseo="tarsons-products-ipo" source="Orion">Tarsons Products IPO</keyword> is all set to list in stock exchanges tomorrow, November 26.</li><li>Investors have shown good interest in the IPO as it has been subscribed 77.49 times.</li><li>The grey market premium of the Indian labware company has come down to ₹170 from ₹200 earlier.</li></ul>Indian labware company Tarsons Products is all set to list its initial public offering (IPO) on stock exchanges tomorrow, November 26. The IPO has shown a good response from investors as it has been subscribed 77.49 times. While the company was looking to raise ₹1,024 crore through the IPO, it received bids for ₹55,625 crore. Investors have bid for 84 crore stocks out of 1.08 stock available for bids. <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Investors </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscription status </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Qualified Institutional Investors </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">115.77 times </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Non-Institutional Investors </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">184.58 times </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Retail </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">10.56 times </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Overall </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">77.49 times </td></tr></tbody></table> However, the grey market premium of the Indian labware company has come down to ₹170 from ₹200 earlier. The IPO consisted of a fresh issue of equity shares worth ₹150 crore and an offer for sale (OFS) of 1.32 crore equity shares that will be sold by promoters and an investor. Some of the company’s clients include Dr Reddy's Laboratories, Metropolis Healthcare, Dr. Lal Path Labs. Tarsons sells nearly one in every ten labware products sold in India. Analysts are betting big on the healthcare sector even post covid and expect the labware products company to continue growing. “COVID has turned out to be a boon for the companies in the healthcare space as worldwide governments have started allocating more funds and people in general have become more conscious towards the healthcare benefits. We expect the firm to grow faster than current CAGR [compound annual growth rate] given the laboratory instrument industry is growing at 20%,” said analysts at Nirmal Bang. Tarsons Products is engaged in designing, developing, manufacturing and supplying a diverse range of quality labware products used in laboratories across research organisations, academic institutes, pharmaceutical firms, diagnostics companies and hospitals. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/how-to-check-go-fashions-ipo-allotment-status/articleshow/87891055.cms">Go Fashion IPO’s allotment status would be announced today, GMP at ₹425</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/reliance-industries-coal-india-and-other-top-stocks-to-watch-out-for-on-november-25/slidelist/87901109.cms">Reliance Industries, Coal India and other top stocks to watch out for on November 25</a>

Tarsons Products IPO listing tomorrow; GMP staggers around ₹170

<ul><li>Shares of Tarsons Products listed at ₹700 while the price band was fixed at ₹635-662 per share.</li><li>The IPO was a hit among investors as it has been subscribed just 77.49 times on the last day of the bidding.</li><li>The market capitalisation of the company stood at ₹3,724 crore.</li></ul>Shares of Indian labware company Tarsons Products made a decent listing on the National Stock Exchange (NSE) and BSE despite weak market trends. The stock listed at ₹700, higher 5.74% on the issue price band of ₹635-662 apiece. Investors were expecting a positive listing despite weak market trends as the fundamentals of the company like becoming debt-free, having strong cash flow looked attractive. “The company has a strong cash flow and it is likely to become debt-free post-IPO [initial public offering] however the valuations look expensive therefore aggressive investors with a long-term view can hold this stock while those who were playing for listing gain should book profit because we are expecting some listing gain of around 20-25% based on subscription figure and grey market trend current GMP 180 (+27%),” said Aayush Agrawal, senior research analyst, merchant banking at Swastika Investmart. Post listing, the market capitalisation of the company stood at ₹3,724 crore, according to BSE data. The shares of Tarsons Products were trading at ₹722, higher by 9% at 10.00 a.m., on November 26. The grey market had indicated a strong listing too as unlisted shares of Tarsons Products were commanding a marginal premium of ₹180 per share. The IPO, which was open between November 15 and November 17, received strong response from investors. It was subscribed 77.49 times on the last day of the bidding. Tarsons Products is engaged in designing, developing, manufacturing and supplying a diverse range of quality labware products used in laboratories across research organisations, academic institutes, pharmaceutical firms, diagnostics companies and hospitals. Some of the company’s clients include Dr Reddy's Laboratories, Metropolis Healthcare, Dr. Lal Path Labs. Tarsons sells nearly one in every ten labware products sold in India. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/startups/news/ratan-tata-backed-upstox-is-now-valued-more-than-its-rivals-zerodha-and-groww/articleshow/87922976.cms">Ratan Tata-backed Upstox is now valued more than its rivals Zerodha and Groww</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/reliance-industries-tarsons-products-asian-paints-and-other-hot-stocks-on-november-26/slidelist/87921730.cms">Reliance Industries, Tarsons Products, Asian Paints and other hot stocks on November 26</a>

Tarsons Products makes a decent stock market debut amid weak market trend; lists at 6% premium

<ul><li>Tarsons Products IPO opens today and closes on November 17.</li><li>The company is looking to raise ₹1,024 crore through its public listing of shares.</li><li>The grey market premium of the Indian labware company is at a premium of ₹200 per share in the grey market.</li></ul>Indian labware company Tarsons Products has opened its IPO today and closes on November 17 with a price band of ₹635-662 per share. The company is looking to raise ₹1,024 crore through its public listing of shares with a fresh issue of equity shares worth ₹150 crore and an offer for sale (OFS) of 1.32 crore equity shares that will be sold by promoters and an investor. Tarsons Products has raised ₹305.96 crore from anchor investors at the upper price band of ₹662 per equity share ahead of its issue. Here are important dates related to the IPO: <table style="border-width: initial; border-style: none;"></colgroup><tbody><tr><td style="border-left:solid #000000 0.75pt;border-right:solid #000000 0.75pt;border-bottom:solid #000000 0.75pt;border-top:solid #000000 0.75pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">Issue details </td><td style="border-left:solid #000000 0.75pt;border-right:solid #000000 0.75pt;border-bottom:solid #000000 0.75pt;border-top:solid #000000 0.75pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;"> </td></tr><tr><td style="border-left:solid #000000 0.75pt;border-right:solid #000000 0.75pt;border-bottom:solid #000000 0.75pt;border-top:solid #000000 0.75pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">Price band </td><td style="border-left:solid #000000 0.75pt;border-right:solid #000000 0.75pt;border-bottom:solid #000000 0.75pt;border-top:solid #000000 0.75pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">₹635 to ₹662 </td></tr><tr><td style="border-left:solid #000000 0.75pt;border-right:solid #000000 0.75pt;border-bottom:solid #000000 0.75pt;border-top:solid #000000 0.75pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">IPO open date </td><td style="border-left:solid #000000 0.75pt;border-right:solid #000000 0.75pt;border-bottom:solid #000000 0.75pt;border-top:solid #000000 0.75pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">November 15 </td></tr><tr><td style="border-left:solid #000000 0.75pt;border-right:solid #000000 0.75pt;border-bottom:solid #000000 0.75pt;border-top:solid #000000 0.75pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">IPO close date </td><td style="border-left:solid #000000 0.75pt;border-right:solid #000000 0.75pt;border-bottom:solid #000000 0.75pt;border-top:solid #000000 0.75pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">November 17 </td></tr><tr><td style="border-left:solid #000000 0.75pt;border-right:solid #000000 0.75pt;border-bottom:solid #000000 0.75pt;border-top:solid #000000 0.75pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">Allotment date </td><td style="border-left:solid #000000 0.75pt;border-right:solid #000000 0.75pt;border-bottom:solid #000000 0.75pt;border-top:solid #000000 0.75pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">November 23 </td></tr><tr><td style="border-left:solid #000000 0.75pt;border-right:solid #000000 0.75pt;border-bottom:solid #000000 0.75pt;border-top:solid #000000 0.75pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">Initiation of refunds </td><td style="border-left:solid #000000 0.75pt;border-right:solid #000000 0.75pt;border-bottom:solid #000000 0.75pt;border-top:solid #000000 0.75pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">November 24 </td></tr><tr><td style="border-left:solid #000000 0.75pt;border-right:solid #000000 0.75pt;border-bottom:solid #000000 0.75pt;border-top:solid #000000 0.75pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">Credit of shares to demat account </td><td style="border-left:solid #000000 0.75pt;border-right:solid #000000 0.75pt;border-bottom:solid #000000 0.75pt;border-top:solid #000000 0.75pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">November 25 </td></tr><tr><td style="border-left:solid #000000 0.75pt;border-right:solid #000000 0.75pt;border-bottom:solid #000000 0.75pt;border-top:solid #000000 0.75pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">IPO listing date </td><td style="border-left:solid #000000 0.75pt;border-right:solid #000000 0.75pt;border-bottom:solid #000000 0.75pt;border-top:solid #000000 0.75pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">November 26 </td></tr><tr><td style="border-left:solid #000000 0.75pt;border-right:solid #000000 0.75pt;border-bottom:solid #000000 0.75pt;border-top:solid #000000 0.75pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">Minimum lot </td><td style="border-left:solid #000000 0.75pt;border-right:solid #000000 0.75pt;border-bottom:solid #000000 0.75pt;border-top:solid #000000 0.75pt;vertical-align:bottom;padding:2pt 2pt 2pt 2pt;overflow:hidden;overflow-wrap:break-word;">22 </td></tr></tbody></table> In the IPO, promoter Sanjive Sehgal will offload up to 3.9 lakh equity shares, Rohan Sehgal will sell up to 3.1 lakh equity shares and investor Clear Vision Investment Holdings will divest up to 1.25 crore equity shares. The company will utilise the proceeds from the fresh issue towards paying debt, funding a part of the capital expenditure for the new manufacturing facility at Panchla in West Bengal and general corporate purposes. Tarsons Products is engaged in designing, developing, manufacturing and supplying a diverse range of quality labware products used in laboratories across research organisations, academic institutes, pharmaceutical firms, diagnostics companies and hospitals. It manufactures a range of quality labware products that helps advance scientific discovery and improve healthcare. The company currently operates through its five manufacturing facilities located in West Bengal. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/shares-of-sigachi-industries-list-at-575-while-the-shares-were-allotted-at-163-per-share/articleshow/87708763.cms">Sigachi Industries more than triples money for IPO investors on listing</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/policybazaar-starts-trading-at-1150-a-premium-of-17/articleshow/87708748.cms">PolicyBazaar starts trading at a premium of over 17%</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/sjs-enterprises-ipo-list-at-1-discount-only/articleshow/87708985.cms">The shares of SJS Enterprises open 1% below the issue price</a>

Tarson Products IPO opens today — Check close date, allotment date and other important details

<ul><li><keyword id="12447226" type="General" weightage="20" keywordseo="tarsons" source="Orion">Tarsons</keyword> Products has received bids for 3.88 crore equity shares versus the 1.08 crore shares up for sale.</li><li>The company intends to raise ₹1,023 crore through its public issue, which includes ₹150 crore as issue of new shares.</li><li>The company will use their capital to repay its debts and spend on the manufacturing facility at Panchla in West Bengal.</li></ul>The initial public offering (IPO) of Tarsons Products continued to witness good demand from investors across the board on the second day of its public issue. The company would be listed on the <a href="https://www.businessinsider.in/stock-market/news/tarson-products-ipo-opens-today-and-closes-on-november-17/articleshow/87709719.cms">stock exchange on November 25</a>. The grey market premium of Tarsons Products shares is <a href="https://www.livemint.com/market/ipo/tarsons-products-ipo-what-gmp-signals-on-second-day-of-subscription-11637035990127.html">reportedly</a> at ₹180. Tarsons Products — which is a labware supplier to the life sciences sector— has received bids for 3.88 crore equity shares versus the 1.08 crore shares that were up for sale. The retail portion has been oversubscribed by 4.74 times and the portion reserved for non-institutional investors has been subscribed 3.98 times. Qualified institutional buyers — which includes banks, mutual funds and others — have subscribed to the IPO 1.30 times. The issue has been subscribed by 3.6 times. Tarsons Products’ public issue will close today, November 17. Interest investors can place their bidding, within a range of ₹645-662 apiece. The lot size has been set at 22 shares,which means that the investors would have to spend at least ₹14,190 to subscribe to the shares. Tarsons Products is engaged in designing, developing, manufacturing and supplying a diverse range of quality labware products used in laboratories across research organisations, academic institutes, pharmaceutical firms, diagnostics companies and hospitals. It manufactures a range of quality labware products that helps advance scientific discovery and improve healthcare. The company intends to raise ₹1,023 crore through its public issue, which comprises ₹ 150 crore as fresh issue. The remaining ₹873 crore will be raised through offer for sale (OfS) and will go to the investors selling their shares in the IPO. The company will use their capital to repay its debts and spend on the manufacturing facility at Panchla in West Bengal. SEE ALSO <a href="https://www.businessinsider.in/business/startups/news/former-myntra-ceo-started-mensa-brand-in-may-and-its-already-worth-a-billion-dollars-with/articleshow/87735832.cms" data-type="tilCustomLink" style="">Former Myntra CEO started Mensa Brand in May ⁠and it’s already worth a billion dollars</a> <a href="https://www.businessinsider.in/cryptocurrency/news/cryptocurrencies-tumble-as-china-continues-its-crackdown-against-mining/articleshow/87738496.cms" data-type="tilCustomLink" style="">Cryptocurrencies tumble as China continues its crackdown against mining</a> <a href="https://www.businessinsider.in/stock-market/news/reliance-industries-makes-for-nearly-third-of-niftys-fall-today-tata-motors-and-maruti-beat-the-trend/articleshow/87736157.cms" data-type="tilCustomLink" style="">Reliance Industries makes for nearly a third of Nifty’s fall today ⁠— Tata Motors and Maruti beat the trend</a>

Tarsons Products IPO — today is the last day to subscribe, GMP at ₹180

<ul><li><keyword id="12496771" type="General" weightage="20" keywordseo="tarsons-products" source="Orion">Tarsons Products</keyword> and <keyword id="2702367" type="General" weightage="20" keywordseo="go-fashion" source="Orion">Go Fashion</keyword> are all set to open their IPOs for investor subscription next week.</li><li>Indian labware company Tarsons Products will open its IPO on November 15 and closes on November 17.</li><li>Go Fashion, the women's bottom-wear products maker, will open its IPO on November 17 and closes on November 22.</li></ul>The frenzy of Initial public offerings (IPO) among investors may continue for some more time as there seems to be no end to back-to-back IPO launches. So far in November, seven firms have completed their biddings. Further, two public issues are opening next week — Tarsons Products and Go Fashion. Tarson Products looks to raise ₹1,024 crore through its public listing of shares Indian labware company Tarsons Products will open its IPO on November 15 and closes on November 17 with a price band of ₹635-662 per share. The IPO consists of a fresh issue of equity shares worth ₹150 crore and an offer for sale (OFS) of 1.32 crore equity shares that will be sold by promoters and an investor. Promoter Sanjive Sehgal will offload up to 3.9 lakh equity shares, Rohan Sehgal will sell up to 3.1 lakh equity shares and investor Clear Vision Investment Holdings will divest up to 1.25 crore equity shares in the IPO. The company will utilise the proceeds from the fresh issue towards paying debt, funding a part of the capital expenditure for the new manufacturing facility at Panchla in West Bengal and general corporate purposes. Tarsons Products is engaged in designing, developing, manufacturing and supplying a diverse range of quality labware products used in laboratories across research organisations, academic institutes, pharmaceutical firms, diagnostics companies and hospitals. It manufactures a range of quality labware products that helps advance scientific discovery and improve healthcare. The company currently operates through its five manufacturing facilities located in West Bengal. Go Fashion is reportedly looking to raise ₹800 crore Go Fashion (India) owns one of the largest women's bottom-wear brands in India under brand Go Colors. The company is <a href="https://www.financialexpress.com/market/ipo-news/go-fashion-ipo-to-open-on-november-17/2367057/">coming out </a>with its IPO on November 17 and will close on November 22. The IPO consists of fresh equity shares worth ₹125 crore and an offer for sale of up to 12,878,389 equity shares by promoters and existing shareholders. As part of the OFS, PKS Family Trust and VKS Family Trust are going to offload 7.45 lakh equity shares each, Sequoia Capital India Investments will sell up to 74.98 lakh shares, India Advantage Fund S4 I will divest up to 33.11 lakh shares and Dynamic India Fund S4 US I will sell up to 5.76 lakh shares. The proceeds from the fresh issue will be used to fund the roll out of 120 new exclusive brand outlets, to support working capital requirements and general corporate purposes. The company is engaged in the development, design, sourcing, marketing and retailing of a range of women’s bottom-wear products under the brand, ‘Go Colors’. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/thelife/personalities/news/the-91-year-old-woman-behind-indias-most-famous-papad-brand-gets-the-fourth-highest-civilian-honour-she-started-with-80/articleshow/87648125.cms">The 91-year old woman behind India’s most famous papad brand gets the fourth highest civilian honour ⁠— she started with ₹80</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/easemytrip-announces-interim-dividend-of-50-after-stellar-profit-growth/articleshow/87648395.cms">EaseMyTrip announces interim dividend of 50% after stellar profit growth</a>

IPO craze continues as two more set to open next week

Reliance Industries, Tarsons Products, Asian Paints and other hot stocks on November 26

<ul><li>Tarsons Products’ ₹1,000 crore IPO had opened on November 15 and will close on November 17.</li><li>Nearly one in every ten lab equipment sold in India is from Tarsons.</li><li>The <keyword id="938640" type="General" weightage="20" keywordseo="grey-market-premium" source="Orion">grey market premium</keyword> of the Indian labware company surged to ₹230 from ₹200.</li><li>Check out the latest news and updates on Business Insider.</li></ul>Today is the second day to subscribe to the Indian labware company Tarsons Products initial public offering (IPO), which will close on November 17. Some of the company’s clients include Dr Reddy's Laboratories, Metropolis Healthcare, Dr. Lal Path Labs. Tarsons sells nearly one in every ten labware products sold in India. The ₹1,024 crore IPO consists of a fresh issue of equity shares worth ₹150 crore and an offer for sale (OFS) of 1.32 crore equity shares that will be sold by promoters and an investor. The company said it will repay debt with the money from the IPO and build its sixth manufacturing facility at Panchla in West Bengal . Tarsons Products is engaged in designing, developing, manufacturing and supplying a diverse range of quality labware products used in laboratories across research organisations, academic institutes, pharmaceutical firms, diagnostics companies and hospitals. <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Broking firms </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Recommendation </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Ventura Securities </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Nirmal Bang </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Angel One </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Investmentz </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe for long term </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Swastika </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Ashika Research </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe for long term </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Choice Broking </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe with caution </td></tr></tbody></table> Analysts are betting big on the healthcare sector even post covid and expect the labware products company to continue growing. The grey market premium of the Indian labware company surged to ₹230 from ₹200 earlier. “Covid has turned out to be a boon for the companies in the healthcare space as worldwide governments have started allocating more funds and people in general have become more conscious towards the healthcare benefits. We expect the firm to grow faster than current CAGR given the laboratory instrument industry is growing at 20%,” said analysts at Nirmal Bang. <div type="image" title="tarsons product" height="900" width="1200" msid="87730870" hostid="261"></div> Besides, the fact that the company cut down its debt by half in two years has impressed analysts. The company total borrowings came down to ₹33 crore in FY21 from ₹64 crore in FY19. Further, the company said it will utilise ₹78 crore from the IPO proceeds to repay/prepayment debt. “The margins of the company have grown significantly on the back of declining debt. The company aims to be debt free post the IPO and is planning for CAPEX (capital expenditure) which will further increase the revenues,” said analysts at Swastika. However, analysts at Choice Broking believe that the sharp spike in growth last year may be a one-off event triggered by the pandemic and the company may find it difficult to maintain the same pace in the future. “There is a respectable import market for the company to capture and also a huge export opportunity arising from the “China plus one” strategy, in case the globe adopts this strategy in the post-Covid period. Thus considering the future growth outlook and the demanded premium valuation, we assign a “Subscribe with Caution” rating for the issue,” the report said. Simply put, the threat of international competition and rising imports is just as valid as the hope of a boom in business for Tarsons. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/policybazzar-and-sigachi-share-price-jump-in-early-trading/articleshow/87730171.cms">Policybazaar gets a boost after an American fund laps up 3.4 million shares and Sigachi hits upper circuit on the morning after listing</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/personal-finance/news/now-you-can-invest-in-global-blockchain-companies-through-this-mutual-fund-heres-how-to-do-it/articleshow/87724967.cms">Now you can invest in global blockchain companies through this mutual fund ⁠— here's how to do it</a>

The IPO from Tarsons, a Bengal-based supplier for Dr Lal Path Labs and Dr Reddy’s, gets a unanimous ‘subscribe’ call from the street

<ul><li>Tarsons Products announced its share allotment status on Tuesday.</li><li>The grey market premium of the Indian labware company Tarsons Products is ₹160.</li><li>The IPO of the company was subscribed 77.49 times on the last day of bidding.</li></ul>The allotment status of Indian labware company Tarsons Products was announced on Tuesday and by now the investors, who unfortunately did not get the shares, should start getting their refunds. If you have not checked whether you received the initial public offering (IPO) allotment or not, <a href="https://www.businessinsider.in/stock-market/news/tarsons-products-ipo-heres-how-to-check-your-allotment-status/articleshow/87857321.cms">click here </a>and follow the procedure. All the investors who got the allotment will receive the shares in their demat account on the date of listing, which in this case is November 26. Usually every applicant gets a message on their registered phone number, highlighting whether the funds are blocked or unblocked. Blocked funds indicate that the shares have been transferred to the investor, whereas the unblocked fund means that the cash has been transferred back to the investor’s bank account. Investors receive a validity period while making the payments for the shares. The IPO amount is usually refunded one day later the IPO allotment or before the end of the validity period. <div type="image" title="If you missed Tarson Products’ IPO allotment, here’s what you should know" msid="87870784" hostid="261"></div> Tarsons Products opened its IPO on November 15 to November 17, at a price band of ₹635-₹662 per share. The IPO received subscriptions for 77.49 times the number of shares offered in the three days of IPO bidding process. The grey market premium of the company’s shares show a premium of ₹160 on November 23. The company has raised over ₹1,024 crore through the IPO of a fresh issue of equity shares worth ₹150 crore and an offer for sale (OFS) of 1.32 crore equity shares that will be sold by promoters and an investor. Tarsons Products is engaged in designing, developing, manufacturing and supplying a diverse range of quality labware products used in laboratories across research organisations, academic institutes, pharmaceutical firms, diagnostics companies and hospitals. SEE ALSO <a href="https://www.businessinsider.in/business/telecom/news/jio-is-slowing-down-in-the-race-to-500-million-subscribers/articleshow/87862415.cms">Jio is slowing down in the race to 500 million subscribers – a goal set by none other than Mukesh Ambani</a> <a href="https://www.businessinsider.in/business/startups/news/nobroker-is-the-38th-indian-startup-to-be-valued-over-a-1-billion-in-2021/articleshow/87867289.cms">NoBroker is the 38th Indian startup to be valued over a billion dollars this year</a> <a href="https://www.businessinsider.in/business/telecom/news/vodafone-idea-hikes-tariffs-by-up-to-500-for-its-popular-plans/articleshow/87864183.cms">Vodafone Idea hikes tariffs by up to ₹500 for its popular plans</a>

If you missed Tarson Products’ IPO allotment, here’s what you should know

From Nykaa to Cipla to 3i infotech — these are some of the themes the market is betting on amid a sell-off

<ul><li><keyword id="28504" type="General" weightage="100" keywordseo="kerala" source="Orion">Kerala</keyword> government has rolled out an online health portal named ‘<keyword id="12588016" type="General" weightage="20" keywordseo="ehealth-Kerala" source="Orion">ehealth.Kerala</keyword>’ to book doctors’ services in all government hospitals online on scheduled dates and time.</li><li>The health card will store all the <keyword id="2440866" type="General" weightage="20" keywordseo="health-data" source="Orion">health data</keyword> of each individual in the state, which can be accessed by the doctor of any hospital.</li><li>Check out the latest news and updates on <a href="https://www.businessinsider.in/">Business Insider</a>.</li></ul>Pinarayi Vijayan-led Kerala government has launched an online health portal named ‘ehealth.Kerala’, which will help people to book doctors’ services in all government hospitals online on scheduled dates and time to avoid overcrowding for outpatient (OP) tickets and slips. The Chief Minister of Kerala, during the launch event, said, “At present, it has been implemented in 311 hospitals where this queue management system has been set-up. People can take appointments of the doctors through the <keyword id="12588015" type="General" weightage="20" keywordseo="ehealth-portal" source="Orion">ehealth portal</keyword> and it will be easier for the doctors to refer patients to other hospitals.” The health card will store all the health data of each individual in the state, which can be accessed by the doctor of any hospital. How to create a unique health ID on the portal? <ol><li>Open the official website ‘<a href="https://ehealth.kerala.gov.in/">ehealth.Kerala</a>’ on any smart device and then click on ‘Register’.</li><li>Then, enter your Aadhaar number. An OTP will be generated at the registered mobile number.</li><li>After entering the OTP, a personal health identification number will be available.</li><li>Then you will receive a 16-digit personal health identification number and password on your registered mobile number.</li></ol>How to book an appointment on the portal? <ol><li>Login into the portal with your unique personal health identification number and password and then click on ‘New appointment’.</li><li>If your booking is a referral, record that information and then select the hospital details and department.</li><li>Tokens for the selected day will appear on your screen after adding your hospital details, you can select your convenient time token.</li><li>You can take a print out of the token as well and you just need to show this at the hospital.</li></ol>SEE ALSO:<a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/tarsons-products-ipo-heres-how-to-check-your-allotment-status/articleshow/87857321.cms">Tarsons Products IPO: Here’s how you can check the allotment status</a><a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/tarsons-products-ipo-heres-how-to-check-your-allotment-status/articleshow/87857321.cms"></a><a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/cryptocurrency/news/jack-dorseys-new-decentralised-crypto-exchange-doesnt-want-to-define-trust-amid-regulatory-uncertainty/articleshow/87852451.cms">Jack Dorsey’s new decentralised crypto exchange doesn’t want to define ‘trust’ amid regulatory uncertainty</a>

Kerala rolls out e-health web portal — Here’s how you can book your doctor’s appointment online

<ul><li>Fall in shares of Reliance, Shree Cements, SBI and others led to sudden drop in Sensex, Nifty 50 in the second half.</li><li>The fall may have been sharper if not for automobile stocks that rallied today on report of improvement in chip shortage.</li><li>Check out the latest news and updates on <a href="https://www.businessinsider.in/">Business Insider</a>.</li></ul>The Indian market slid sharply in the second half of trade on Tuesday (November 16). Nifty 50 broke below the 18,000 mark and Reliance Industries (RIL) contributed to nearly 30% of the fall, as at 2:40 p.m. 37 of the 50 stocks were in decline at the time. If not for the rally in automobile stocks like Tata Motors and Maruti Suzuki, the fall may have been sharper. The sell-off was the worst in pharmaceuticals, banks ⁠— particularly the state-owned ones like State Bank of India (SBI) ⁠— and the energy index fell over a percent largely due to the sell off in RIL shares. Top losers : Nifty 50 <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;" class="redcator-table-advance"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Shree Cements </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-3% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">SBI </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-2.4% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Tata Consumer </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-2.3% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">NTPC </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-2% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Reliance </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-3% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipla </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-1.6% </td></tr></tbody><tbody></tbody></table>As of 3:30 PM on November 16 “Some correction is expected as investors are selling PSU and some other stocks to make way for LIC, which is expected to be launched around February. This can be one of the triggers for the fall. Another 5% correction could happen in the next 15-20 days due to global weak sentiment,” said Abhishek Jain, chief market strategist at BP Equities. Cements stocks like Shree Cements fell after a report indicated that cement companies have dropped plans to hike prices for the month of November. “Cement prices have seen some correction especially in eastern market and in western market there was a hike after Diwali, which has been reversed right now,” added Jain. The top five gainers on the Nifty 50 were all auto stocks after Morgan Stanley said that the chip shortage, which had stalled production for car makers around the world, may be easing finally. A similar commentary from Uttar Pradesh-based electronic products manufacturer Dixon Technologies took the shares higher. <div type="image" title="dixon" height="900" width="1200" msid="87736216" hostid="261"></div> Some of the most traded stocks on the National Stock Exchange ⁠— the largest by volume ⁠— were auto parts makers Mahindra CIE and Suprajit Engineering, and cloud solutions company Tanla Platforms. All three stocks saw nearly ten times the volume of shares traded on an average in the last five days, and all three of them gained over 5% today. Aegis Health and P&amp;G Health hit a 52-week low today. Investors continued to dump shares of IndusInd Bank and Hindalco and both shares are now among the biggest losers on the Nifty 100 index in the last one month. Indian Railway Catering and Tourism Corporation (IRCTC), the billion dollar company that has a near monopoly in railway ticket bookings and catering, jumped 1.8% today. Still, it’s shareholders have lost over 21% of the value in the last one month. Top losers on Nifty 100 in the last one month <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;" class="redcator-table-advance"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Stock </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Change </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">IndusInd Bank </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-15.45% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Jindal Steel and Power </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-13.4% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Hindalco </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-13.2% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Coal India </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-13.2% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">PI Industries </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-11.66% </td></tr></tbody><tbody></tbody></table> SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/startups/news/former-myntra-ceo-started-mensa-brand-in-may-and-its-already-worth-a-billion-dollars-with/articleshow/87735832.cms">Former Myntra CEO started Mensa Brand in May ⁠and it’s already worth a billion dollars with</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/analysts-say-subscribe-to-tarsons-ipo-a-supplier-for-dr-lal-path-labs-and-dr-reddys-from-bengal/articleshow/87730889.cms">The IPO from Tarsons, a Bengal-based supplier for Dr Lal Path Labs and Dr Reddy’s, gets a unanimous ‘subscribe’ call from the street</a>

Reliance Industries makes for nearly a third of Nifty’s fall today ⁠— Tata Motors and Maruti beat the trend

Two doses of <keyword id="9485939" type="General" weightage="20" keywordseo="Covaxin" source="Orion">Covaxin</keyword> are 50 per cent effective against symptomatic COVID-19, according to the first real-world assessment of India's indigenous coronavirus vaccine published in <keyword id="456544" type="General" weightage="20" keywordseo="The-Lancet" source="Orion">The Lancet</keyword> Infectious Diseases journal. The results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns. The latest study assessed 2,714 hospital workers at the <keyword id="6365231" type="General" weightage="20" keywordseo="All-India-Institute-of-Medical-Sciences" source="Orion">All India Institute of Medical Sciences</keyword> (AIIMS) in Delhi, from April 15 May 15, who were symptomatic and underwent RT-PCR test for COVID-19 detection. Researchers noted that the Delta variant was the dominant strain in India during the study period, accounting for approximately 80 per cent of all confirmed COVID-19 cases. Covaxin, developed by Hyderabad-based <keyword id="149108" type="General" weightage="20" keywordseo="Bharat-Biotech" source="Orion">Bharat Biotech</keyword> in collaboration with the National Institute of Virology, Indian Council of Medical Research (NIV-ICMR), Pune, is an inactivated whole virus vaccine administered in a two-dose regimen, 28 days apart. In January this year, Covaxin was approved for emergency use in India for people aged 18 and above. The World Health Organization (WHO) added the vaccine to its list of approved emergency use COVID-19 vaccines earlier this month. The latest study was conducted during India's second COVID-19 surge and in healthcare workers who were primarily offered Covaxin. "Our study offers a more complete picture of how BBV152 (Covaxin) performs in the field and should be considered in the context of COVID-19 surge conditions in India, combined with the possible immune evasive potential of the Delta variant," said Manish Soneja, Additional Professor of Medicine at AIIMS New Delhi. "Our findings add to the growing body of evidence that rapid vaccine rollout programmes remain the most promising path to pandemic control while public health policies must continue to include additional protective measures, such as mask-wearing and social distancing," Soneja said in a statement. The COVID-19 vaccination centre at AIIMS New Delhi exclusively offered Covaxin beginning January 16 this year to all of its 23,000 employees. Researchers evaluated the effectiveness of the vaccine against symptomatic RT-PCR confirmed SARS-CoV-2 infection. Of the 2,714 employees in the study population, 1,617 people tested positive for SARS-CoV-2, the virus that causes COVID-19, and 1,097 tested negative. Positive cases were matched to negative RT-PCR tests (controls). The odds of vaccination with Covaxin were compared between cases and controls and adjusted for occupational exposure to COVID-19, previous SARS-CoV-2 infection, and infection dates. The study found that the vaccine effectiveness against symptomatic COVID-19 after two doses of Covaxin with the second dose administered 14 or more days before undergoing RT-PCR testing was 50 per cent. The effectiveness of two vaccine doses remained stable over the seven-week follow-up period, the researchers said. The adjusted vaccine effectiveness of the first dose, estimated after seven and 21 days, was low, which is consistent with the performance of other preventives against the Delta variant, they said. "Findings from the study confirm previous research indicating that two doses of BBV152 are required to achieve maximum protection and that all vaccine roll-out plans must follow the recommended dosing schedule," said Parul Kodan, Assistant Professor of Medicine at AIIMS New Delhi. "More research is needed to better understand how these findings translate to BBV152's effectiveness against delta and other variants of concern, especially related to severe COVID-19 infection, hospitalisation, and deaths," Kodan said. The authors acknowledge that the vaccine <keyword id="12595121" type="General" weightage="20" keywordseo="effectiveness-of-Covaxin" source="Orion">effectiveness of Covaxin</keyword> estimated in this study is lower than the efficacy reported by the recently published phase 3 trial. They noted that several factors may be responsible for the lower vaccine effectiveness in the latest study. The researchers said this study population only included hospital employees who may have a higher risk of exposure to COVID-19 infection than the general population. The research was conducted during the peak of India's second wave of COVID-19 with high test positivity rates for both hospital employees and residents of Delhi, they said. Prevalence of circulating variants of concern, especially Delta, may have also contributed to the vaccine's lower effectiveness, according to the researchers. The authors acknowledge several limitations to their study. The study does not estimate the vaccine effectiveness against hospitalisation, severe disease, and death, which require further assessment, they noted. Also, the study was not designed to estimate vaccine effectiveness for different time intervals after vaccination or to determine if vaccine effectiveness changed over time, the researchers added. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/url-go-fashion-ipo-allotment-tomorrow-and-gmp-is-falling-every-day/articleshow/87876496.cms">Go Fashion IPO allotment tomorrow; GMP on a downward trend</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/if-you-missed-tarson-products-ipo-allotment-heres-what-you-should-know/articleshow/87870822.cms">If you missed Tarson Products’ IPO allotment, here’s what you should know</a>

You Searched For "tarson products ipo" and got 13 results

Tarsons Products IPO: Here’s how you can check the allotment status

Bhakti Makwana

Tarsons Products IPO listing tomorrow; GMP staggers around ₹170

Bhakti Makwana

Tarsons Products makes a decent stock market debut amid weak market trend; lists at 6% premium

Bhakti Makwana

Tarson Products IPO opens today — Check close date, allotment date and other important details

Bhakti Makwana

Tarsons Products IPO — today is the last day to subscribe, GMP at ₹180

Kritti Bhalla

IPO craze continues as two more set to open next week

Bhakti Makwana

Reliance Industries, Tarsons Products, Asian Paints and other hot stocks on November 26

Rounak Jain

The IPO from Tarsons, a Bengal-based supplier for Dr Lal Path Labs and Dr Reddy’s, gets a unanimous ‘subscribe’ call from the street

Bhakti Makwana

If you missed Tarson Products’ IPO allotment, here’s what you should know

Kritti Bhalla

From Nykaa to Cipla to 3i infotech — these are some of the themes the market is betting on amid a sell-off

Bhakti Makwana

Kerala rolls out e-health web portal — Here’s how you can book your doctor’s appointment online

Vaamanaa Sethi

Reliance Industries makes for nearly a third of Nifty’s fall today ⁠— Tata Motors and Maruti beat the trend

Bhakti Makwana

Covaxin shows 50% effectiveness against symptomatic COVID-19 in real-world assessment, says Lancet study

PTI

Popular Keywords

Buying Guides